<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04048044</url>
  </required_header>
  <id_info>
    <org_study_id>HIH RM</org_study_id>
    <nct_id>NCT04048044</nct_id>
  </id_info>
  <brief_title>EFFECTS OF RejuvaMatrix ™ ON TELOMERES</brief_title>
  <official_title>THE EFFECTS OF THE RejuvaMatrix ™ ON TELOMERES</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Holos Institutes of Health, Inc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Holos Institutes of Health, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lying for 30 to 60 minutes daily in a field of 75 decibels of electromagnetic energy at 54 to
      78 GHz will allow telomeres of white blood cells to regenerate
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Individuals who are post menopausal and who do not have an implanted electronic device, such
      as a pacemaker will have base line white blood cell telomeeres measured at Repeat Diagnostics
      in Vancouver. They will be supplied with a two inch foam mat in the center of which is copper
      screen with one pound of crushed sapphire. The mat looks like a mattreess and is placed on
      top of the regular mattress. Participants are provided with a Tesla coil to be attached to a
      copper wire coming from the copper screen. They will also be provided with a timer so that
      they can set the Tesla coil to be activated for a maximum of 60 minutes while they sleep.

      Telomeres will be measured at the end of each year for 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2009</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Length of telomeres after 5 years compared with baseline</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Symptom Index</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Telomeres</condition>
  <arm_group>
    <arm_group_label>Telomere length, GigaHz exposure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Measurement of white blood cell telomeres before and yearly for 5 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Exposure to GHz electromagnetic energy (RejuvaMatrix)</intervention_name>
    <description>75 decibels of 54 to 78 GHz daily for 60 minutes</description>
    <arm_group_label>Telomere length, GigaHz exposure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -

        Exclusion Criteria:

          -  Implanted electronic device

          -  Major, debilitating disease

          -  Person living with an individual who has an implanted device

          -  Person who is or could become pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>May 10, 2012</study_first_submitted>
  <study_first_submitted_qc>August 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2019</study_first_posted>
  <last_update_submitted>August 6, 2019</last_update_submitted>
  <last_update_submitted_qc>August 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Holos Institutes of Health, Inc</investigator_affiliation>
    <investigator_full_name>C. Norman Shealy</investigator_full_name>
    <investigator_title>M.D., Ph.D.</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

